EGFR amplification

Across glioma subtypes, OCAv3 enabled integrated classification in most cases, particularly in oligodendroglioma and glioblastoma, by simultaneously assessing SVs and CNVs. Implementation in the prospective clinical cohort reduced required FISH studies by 90%, significantly shortened turnaround times, and decreased molecular testing costs.

P3, N=18, Completed, University of Texas Southwestern Medical Center | Active, not recruiting --> Completed | Trial completion date: Jun 2027 --> Oct 2025

P1, N=61, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026

These findings suggest that a subset of morphologically defined cerebellar glioblastomas in adults represents the dpHGG, H3-/IDH-WT, RTK1 subtype. Recognition of this underappreciated manifestation is important for accurate tumor classification, and further accumulation of well-characterized cases is required to clarify its clinical significance.

The E + B combination showed modest anti-tumor activity in patients with heavily pretreated EGFR-amplified solid cancers. While NGS may help identify new applications for existing drugs, additional investigations are warranted to validate the efficacy and benefit of E + B in this population.

We retrospectively analyzed 20 patients with newly diagnosed primary IDH-wildtype glioblastoma who underwent gross-total resection followed by standard radiotherapy and temozolomide treatment between 2016 and 2022...However, given the limited sample size, the selection of extreme survival groups, and the predominance of chromosomal polysomy detected by FISH, these findings should be interpreted as hypothesis-generating only. Further validation in larger cohorts using high-resolution genomic methods is warranted.

Additionally, the manuscript emphasizes novel therapeutic strategies, such as nanomedicine, oncolytic virotherapy, immunotherapy, tumor-treating fields, and phytochemical-based interventions, as well as the increasing significance of artificial intelligence and machine learning in diagnosis and personalized treatment. Lastly, this review integrates mechanistic and translational insights to establish a framework addressing blood-brain barrier limitations, therapeutic resistance, and immune evasion, thereby facilitating the advancement of precision medicine approaches for enhanced GBM outcomes.

Mobocertinib demonstrated clinically meaningful activity, regardless of previous exposure to amivantamab, in EGFR exon 20 insertion-positive NSCLC subjects. Acquired resistance mechanisms to mobocertinib were diverse, which poses challenges to sustained efficacy, emphasizing the need for development of a tailored subsequent therapeutic strategy.

The coexistence of GBM and meningioma appears mostly coincidental, driven by distinct molecular pathways rather than a common progenitor. Despite the benign nature of the associated meningioma, prognosis is dictated by the aggressive GBM component. Early surgical intervention and modern adjuvant therapy remain essential for optimizing survival in these complex cases.

While vebreltinib appears clinically advantageous over crizotinib for METex14-mutated NSCLC, the therapeutic benefits did not reach statistical significance in this study. The observed differential response patterns and resistance mechanisms suggest distinct biological behaviors to type Ia and Ib MET TKIs that warrant further investigation. These findings underscore the need for larger prospective studies to validate the potential superiority of vebreltinib and to better characterize the molecular determinants in NSCLC.

This study highlights the potential clinical utility of CSF-ctDNA analysis for evaluating and reclassification of patients with gliomas.

Our review did not uncover features to improve grading of oligodendroglioma, IDH-mutant and 1p/19q-codeleted, although CNS WHO grade 3 tumors with elevated mitotic rates, yet lacking necrosis, microvascular proliferation, CDKN2A/B homozygous deletion and MRI contrast enhancement, may be associated with extended survival. Implementing evidence-based criteria for risk stratification and grading will improve guidance for clinical decision-making.